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Herbal drug BNO 1016 is safe and effective in the treatment of acute viral
rhinosinusitis
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Abstract
Conclusion: Daily intake of 480 mg of BNO 1016 for 15 days is an effective treatment in acute viral rhinosinusitis. Objectives:
The pooled efﬁcacy data of two similar randomized placebo-controlled clinical trials were analyzed. Safety was evaluated on the
basis of the individual trials. Methods: The efﬁcacy analysis was based on 589 patients. Treatment was performed orally with
either 3  160 mg BNO 1016 (n = 294) or 3  placebo (n = 295) for 15 days. In both trials patients underwent ﬁve visits to the
investigational sites. Symptoms were evaluated according to the EPOS 2012 guideline. Ultrasonography was used to conﬁrm
the diagnosis at onset of treatment and the remission of symptoms at the last visit. Efﬁcacy was evaluated by the investigator as
the mean major symptom score (MSS) at the end of treatment (visit 5, day 14). Patients reported symptoms and social/
emotional consequences of rhinosinusitis using a quality of life questionnaire (SNOT-20 GAV). Results:MSS improved during
the treatment period by a mean of 10.02 ± 1.61 score points to 2.47 ± 2.55 for BNO 1016 and of 9.87 ± 1.52 to 3.63 ± 3.63 for
placebo. Differences between treatment groups at end of therapy (1.16 ± 3.14 score points; p < 0.0001) and patient-assessed
quality of life (p = 0.0015) were statistically signiﬁcant in favor of BNO 1016.
Keywords: Dry extract, major symptom score, MSS, Sino-Nasal Outcome Test (SNOT-20), EPOS 2012, ultrasonography
Introduction
During recent years the concept rhinosinusitis has
been introduced to elucidate that an inﬂammation
occurs simultaneously in the nose and the paranasal
sinuses. A rhinosinusitis usually involves one or
several paranasal sinuses. It might be conﬁrmed by
ultrasonography or as an opaciﬁcation in X-ray inves-
tigation. According to the European Position Paper
on Rhinosinusitis and Nasal Polyps (EPOS 2012)
acute rhinosinusitis (ARS) is deﬁned – besides as
an inﬂammation of the nose and paranasal sinuses –
by two or more of the following characteristic symp-
toms: nasal congestion or secretion combined with
facial pain or pressure or loss/reduction of smell [1].
Additional symptoms such as fever, fatigue or
headache may occur.
Acute rhinitis is the ﬁrst step in the development of
rhinosinusitis. The demarcation of acute and chronic
rhinosinusitis is mainly deﬁned by length of the
disease and not by speciﬁc symptoms. According to
the deﬁnitions in EPOS 2012 an ARS is completely
healed without remaining symptoms after 12 weeks,
while in a chronic rhinosinusitis one or several symp-
toms still remain after that period. An acute viral
rhinosinusitis lasts less than 10 days while an acute
post-viral rhinosinusitis persists after 10 days. In the
latter case there is often a biphasic symptom pattern
with persisting or impairing symptoms by the end of
the 10-day period.
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ARS is predominantly caused by a number of
viruses (rhinovirus, parainﬂuenza-1 and -2, corona-
virus, and inﬂuenza viruses), which all induce an
increase of proinﬂammatory cytokines and neutro-
phils [2]. A similar type of reaction occurs also in a
bacterial infection. Thus, an ARS can easily be mis-
diagnosed as a bacterial infection and is therefore
treated with antibiotics, which at this stage of the
disease does not improve healing.
ARS is the most common of all infectious diseases
and has an enormous socio-economic impact on
society besides the individual discomfort with a
reduced quality of life [3]. The treatment strategy is
to reduce the severity of the symptoms, minimize the
duration of the disease, and prevent complications as
well as further development into a chronic disease.
During recent years a new treatment modality of
ARS has been introduced – phytotherapeutic agents
[4–6]. BNO 1016 (Bionorica SE, Neumarkt,
Germany) is a novel drug based on a dry extract of
a ﬁxed combination of ﬁve herbal drugs comprising
Gentian root (Gentianae radix), Primula ﬂower
(Primula ﬂos), Sorrel herb (Rumicis herba), Elder
ﬂower (Sambuci ﬂos), and Verbena herb (Verbenae
herba) in the ratio 1:3:3:3:3. This drug is a standard-
ized high-dosage product for the treatment of ARS.
Pharmacodynamic studies have demonstrated in both
in vitro and animal models that BNO 1016 has anti-
microbial and antiviral effects including secretolytic
and anti-inﬂammatory activities [6]. A previous
phase 2b/3 study has documented positive efﬁcacy
and safety of BNO 1016 with a daily dose of 160 mg t.
i.d. for 15 days [7]. This was conﬁrmed in a subse-
quent conﬁrmatory phase 3 trial [8].
For the present evaluation, data from the phase 2b/
3 (ARhiSi-1) and the phase 3 (ARhiSi-2) trial were
pooled to conﬁrm the observed treatment effect for a
bigger patient population. The analysis was based on
589 patients to compare the efﬁcacy of 480 mg of
BNO 1016 daily (3  160 mg) with placebo in the
treatment of ARS.
Material and methods
Patients
For the analysis of the pooled data inclusion criteria
of the ARhiSi-2 trial were applied. Adult outpatients
of both sexes aged ‡ 18 and £ 75 years with a clinical
diagnosis of ARS (ICD-10: J01.9), conﬁrmed by
ultrasonography of the maxillary sinuses for all
patients, were considered for the analysis. ARS
was deﬁned as sudden onset of at least three of
the main symptoms (rhinorrhea/anterior discharge,
postnasal drip, nasal congestion, headache, and
facial pain/pressure). At enrolment, the symptoms
must have lasted for 3 days or less. All included
patients must have presented an investigator-
evaluated major symptom score (MSS) of ‡ 8 and
£ 12 (of maximal 15 score points). In addition, nasal
congestion must be present and a mild to moderate
facial pain/pressure (score of ‡ 1 and £ 2). Facial
pain was limited to moderate intensity to conﬁne the
enrolment to patients with a non-complicated ARS
only.
Patients treated with corticosteroids or antibiotics
(locally or systemically) within 4 weeks before the ﬁrst
visit to the investigator (‘inclusion visit’) were
excluded. This also comprised subjects using medi-
cation for common cold-like symptoms, immunomo-
dulating drugs (within 7 days before inclusion),
pregnant or lactating women, and subjects with severe
diseases of kidney or liver, severe somatopathic or
neurological and/or psychiatric diseases.
Design of the analysis
The analysis was based on two similar prospective
randomized, double-blind, placebo-controlled, paral-
lel-group, multicenter studies performed during
2009–2010 in 37 centers (16 specialists in otorhino-
laryngology, 21 specialists in internal medicine, and
general practitioners) across Germany. At visit 1/day
0 outpatients suffering from ARS were included,
randomized, and provided written consent. Treat-
ment was performed orally with either 3  160 mg
BNO 1016 or 3  placebo for 15 days. Treatment
allocation in both studies was according to the ratio 1:
1. Neither the subjects nor the investigator knew the
identity of the medication, allowing treatment in a
double-blind manner.
Patientsdocumented their symptomsdailyduring the
treatmentphase.Ateveryvisit tothestudycenter(days3,
7, 10, and 14; visits 2, 3, 4, and 5, respectively) the
investigator evaluated the ﬁve symptoms of MSS and
response to treatment. Additionally during the visits the
patients completed the health-related quality of life
questionnaire (Sino-Nasal Outcome Test-20 German
Adapted Version, SNOT-20 GAV) [9].
Ultrasonography of paranasal sinuses was per-
formed in both studies at the ﬁrst visit to conﬁrm
the diagnosis. Ultrasonography at the end of the treat-
ment (visit 5) was performed in the second study only.
The studies were approved by the German author-
ity and received a favorable opinion from the ethics
committee and were in accordance with the Declara-
tion of Helsinki and the ICH Harmonised Tripartite
Guideline for Good Clinical Practice (CPMP/ICH/
135/95).
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Efﬁcacy measurements
Efﬁcacy end points. All efﬁcacy analyses were based on
the pooled data of the ARhiSi-1 and ARhiSi-2 trials,
see the section on Statistical analysis.
The primary end point for the pooled analysis set
was the mean MSS at visit 5 (day 14, full analysis set,
FAS, and per-protocol population, PP). Additionally
the single symptoms of the MSS at visit 5 (day 14)
were analyzed (FAS and PP). Furthermore, the
SNOT-20 symptom score as total sum at visit 3
(day 7) and at visit 5 (day 14) were analyzed for
FAS and PP. Additionally the responders classiﬁed
by the investigator on a 4-point rating scale at visit
2 (day 3), visit 3 (day 7), visit 4 (day 10), and visit
5 (day 14) were analyzed (FAS and PP).
Assessment of symptom severity. Investigators rated the
severity of each of the ﬁve symptoms of the MSS at
each visit using a four-point rating scale of increasing
severity (0 = none/not present, 1 =mild, 2 =moderate,
3 = severe). Pain parameters and postnasal drip were
rated according to the patients’ descriptions.
Major symptom score (MSS). The MSS combines the
ﬁve most relevant symptoms of rhinosinusitis based
on expert clinician recommendations (rhinorrhea/
anterior discharge, postnasal drip, nasal congestion,
headache, and facial pain/pressure) and has been
employed as primary efﬁcacy criterion in several clin-
ical trials [10–12]. The MSS was calculated as the
sum of the ﬁve single symptom assessments.
Assessment of responders and non-responders to treatment.
Overall response to treatment was assessed by the
investigator at each visit using a four-point rating scale
(0 = symptoms healed/cured; 1 = symptoms improved
compared with visit 1; 2 = symptoms unchanged
compared to visit 1, 3 = symptoms deteriorated com-
pared with visit 1). Patients who were cured or
reported improved symptoms (0 and 1 rated score)
were classiﬁed as responders, whereas patients with
unchanged or deteriorated symptoms (2 and 3 rated
score) were classiﬁed as non-responders.
Statistical analyses
General deﬁnition of population. Only the treatment
arms ‘placebo’ and ‘BNO 1016 480 mg’ of the
ARhiSi-1 trial were included in the combined anal-
ysis: as inclusion and exclusion criteria of ARhiSi-2
were applied for the combined analysis, patients in the
ARhiSi-1 study with facial pain/pressure > 2 or
MSS > 12 or MSS < 8 at inclusion were excluded
from the analysis sets, as this was a violation of an
inclusion criterion in ARhiSi-2. The allocation of
patients to the different analysis sets was done accord-
ing the ‘Blinded Review Meetings’ of the respective
ARhiSi-1 and ARhiSi-2 trials.
Analysis sets and handling of missing data. Efﬁcacy
analyses were performed primarily on the FAS, which
comprised data for all randomized patients with acute
rhinosinusitis who had received at least one dose of the
studymedicationandat leastoneevaluationof efﬁcacy.
The PP comprised all randomized patients from the
FAS excluding those with major protocol violations.
For evaluation of safety no pooling of data was per-
formed. Instead the safety evaluable population (SEP)
of each trial was used to describe the safety results.
Here, the baseline data were used for imputation of
missing values in case of early drop-out patients due
to insufﬁcient efﬁcacy for the FAS population.
Generally, in case of missing values resulting from
the situation that patients recovered from the disease
and discontinued the study, the last documented
value of each efﬁcacy end point was used for the
imputation of the respective ‘missing’ values concern-
ing all following visits that were not performed (last
observation carried forward, LOCF).
In case the patient withdrew from the study for
reasons associated with the study medication such as
an unexpected worsening of disease/condition during
study or lackof efﬁcacy, theworst categorywasused for
the global assessment of efﬁcacy by the investigator.
In case of missing item values for the calculation of
the SNOT-20 symptom score the worst item category
was used if not more than two item values were
missing, otherwise it was regarded as missing.
Statistical methods
All data were analyzed using the SAS version 9 statis-
tical software. As most of the statistical tests were
performed one-sided, p values £ 0.025 indicate sta-
tistical signiﬁcance.
If not indicated otherwise, deviations are indicated
as standard error of the mean (SEM).
All efﬁcacy analyses were performed with the
pooled data set (see Statistical analyses). In the anal-
ysis of the pooled data the primary end point of
ARhiSi-2 was evaluated using the analysis of covari-
ance (ANCOVA).
A difference of one score point in MSS between the
treatment groups was prospectively (in analogy to
ARhiSi-2) judged to be clinically relevant.
All secondary end points were analyzed
exploratively. Categorical variables were tested by
44 R. Jund et al.
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the chi-squared test. Continuous data were analyzed
by ANCOVA similarly to the primary end point or by
the Cochran–Mantel–Haenszel test. Baseline values
were compared between treatment groups and tested
by the Mann–Whitney–Wilcoxon test (continuous
variables) or chi-squared test (categorical test).
Results
Patient allocation
The patient allocation is shown in Figure 1. A total of
303 patients were allocated to the BNO 1016 treat-
ment group whereas 297 were allocated to the placebo
group in the pooled data set. Also, 589 of these
600 randomized patients were considered for the
FAS, 294 in the BNO 1016 group (97%) and 295
in the placebo group (98.2%).
The criteria for the PP were fulﬁlled by
213 (70.3%) patients in the BNO 1016 group and
220 (74.1%) patients in the placebo group.
Efﬁcacy results
Study duration and treatment compliance. The median
participation in the study was 29 days for both groups,
with a range of 3–57 days with BNO 1016 and 3–
86 days with placebo. Compliance with treatment,
according to tablet count, was 99.7% in the BNO
1016 group and 100.2% in the placebo group.
Major symptom score (MSS). The baseline (mean
MSS) at enrolment was without statistical differences
between the two treatment groups (Table I). MSS
improved gradually in both groups during the 15-day
treatment period by a mean of 10.02 ± 1.61 to 2.47 ±
2.55 for BNO1016 and 9.87 ± 1.52 to 3.63 ± 3.63 with
placebo (Table I, Figure 2). The difference between
treatment groups at visit 5was statistically signiﬁcant in
favor of the BNO 1016 product (FAS, p < 0.0001).
An obvious difference in MSS between the two
groupswasalreadyevident at visit 4 (day10), indicating
a faster recovery for the BNO 1016 group, showing a
differenceof0.94scorepointswithmeanscoringvalues
Entered/randomized
BNO 1016 480 mg
ARhiSi-1 & ARhiSi-2
Condition: Patients with facial pain/pressure £ 2 and MSS £ 12
and treatment with BNO 1016 480 mg or Placebo
Placebo
(n = 303) (n = 297)
Safety evaluable population
Full analysis set
(n = 301)
(Withdrawal of informed consent
(n = 2))
(No exposure to study
medication (n = 1))
(No post-baseline efficacy data
available (n = 5),
Target diagnosis not confirmed
(n = 2))
(Relevant protocol deviations
(n = 90))
(Relevant protocol deviations
(n = 77))
(No post-baseline efficacy data
available (n = 1))
(n = 296)
(n = 294) (n = 295)
Per-protocol set
(n = 213) (n = 220)
Figure 1. Patient allocation.
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4.11 versus 5.05. At visit 5 (day 14) the values were
2.47 ± 2.55 (BNO 1016) and 3.63 ± 3.63 (placebo),
respectively – a difference of 1.16 ± 3.14 score points.
This translates into an almost 3 day faster recoverywith
BNO 1016 (day 11 and day 14, respectively). The
difference between treatment groups at the end of
therapy for the PP analysis set accounted for 1.70 ±
3.13 score points (p < 0.0001). This equates to a 4 day
faster recovery with BNO 1016 at the end of therapy
(day 10 and day 14, respectively).
Single symptoms of MSS at visit 5 (day 14) are
shown in Table II. In the FAS each individual symp-
tom shows a statistical signiﬁcance in favor of BNO
1016 (p < 0.0001).
Response to treatment. Absolute and relative treatment
results are summarized in Table III. A statistically
signiﬁcant improvement (for both FAS and PP) in
favor of BNO 1016 was seen already on day 7 (visit 3).
Figure 3 shows combined analysis of ARhiSi-1 and
ARhiSi-2: response (healed or improved) to treatment
from visit 2 (day 3) to visit 5 (day 14).
Quality of life measures. SNOT-20 total score results
are shown in Table IV. A highly signiﬁcant difference
in favor of BNO 1016 was evident at the end of
treatment (p = 0.0015).
Safety results. Serious adverse events (SAEs) were not
reported in either theARhiSi-1 or theARhiSi-2 trial. In
ARhiSi-1 a total of 42 adverse events (AEs) occurred in
33 patients of the SEP (safety evaluable population,
n = 450): 33 AEs in 26/300 patients (8.7%) under
Table I. Major symptom score (MSS) from visit 1 (day 1) to visit 5 (day 14): FAS and PP.
FAS PP
MSS by visit
BNO 1016 480 mg
(n = 294)
Placebo
(n = 295)
BNO 1016 480 mg
(n = 213)
Placebo
(n = 220)
Visit 1 (day 0) Mean (SD) 10.02 (1.61) 9.87 (1.52) 9.70 (1.28) 9.65 (1.27)
Visit 2 (day 3) Mean (SD) 7.71 (2.40) 7.86 (2.71) 7.50 (2.11) 7.78 (2.53)
Visit 3 (day 7) Mean (SD) 5.54 (2.74) 6.15 (3.13) 5.15 (2.45) 6.14 (3.06)
Visit 4 (day 10) Mean (SD) 4.11 (2.66) 5.05 (3.44) 3.77 (2.32) 4.93 (3.42)
Visit 5 (day 14)*† Mean (SD) 2.47 (2.55) 3.63 (3.63) 2.06 (2.31) 3.76 (3.76)
p value*† p < 0.0001 p < 0.0001
Difference [placebo – BNO 1016 480 mg] (SD) 1.17 (3.14) 1.70 (3.13)
*One-sided; alpha = 0.025.
†ANCOVA.
FAS, full analysis set; PP, per-protocol population; SD, standard deviation.
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Figure 2. ARhiSi combined analysis of ARhiSi-1 and ARhiSi-2: mean MSSINV ± 1.96*SEM from day 0 to day 14 (FAS, full analysis set;
n = 589). MSS, major symptom score; V, visit.
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treatment with BNO 1016 (2 treatment groups with
BNO 1016 in a daily dose of 240 mg or 480 mg) and
9 AEs in 7/150 patients (4.7%) under treatment with
placebo. In ARhiSi-2 a total of 53 AEs occurred in
46 patients of the SEP (n = 385): 21 AEs in 19/194
patients (9.8%) under treatment with BNO 1016
480 mg and 32 AEs in 27/191 patients (14.1%) under
treatment with placebo. The majority of AEs reported
under BNO 1016 were of mild to moderate intensity.
Discussion
This analysis shows that oral administration of 480mg
(3 160 mg) of the herbal drug BNO 1016 is effective
Table II. Single symptoms of major symptom score (MSS) at visit 5 (day 14): FAS and PP.
FAS, mean (SD) PP, mean (SD)
Single symptom
MSS at visit 5 (day 14)
BNO 1016 480 mg
(n = 294)
Placebo
(n = 295)
BNO 1016 480 mg
(n = 213)
Placebo
(n = 220)
Rhinorrhea 0.62 (0.65) 0.86 (0.82) 0.56 (0.63) 0.87 (0.85)
p value*† < 0.0001 p value*† < 0.0001
Postnasal drip 0.53 (0.71) 0.79 (0.85) 0.43 (0.65) 0.80 (0.87)
p value*† < 0.0001 p value*† < 0.0001
Nasal congestion 0.71 (0.80) 0.91 (0.95) 0.61 (0.75) 0.93 (0.95)
p value*† = 0.0028 p value*† = 0.0001
Headache 0.31 (0.62) 0.57 (0.85) 0.23 (0.55) 0.61 (0.88)
p value*† < 0.0001 p value*† < 0.0001
Facial pain 0.31 (0.64) 0.51 (0.82) 0.23 (0.58) 0.56 (0.87)
p value*† 0.0003 p value*† < 0.0001
*One-sided; alpha = 0.025.
†ANCOVA.
FAS, full analysis set; PP, per-protocol population; SD, standard deviation.
Table III. Response (healed or improved) to treatment from visit 2 (day 3) to visit 5 (day 14): FAS and PP.
FAS PP
Response to treatment
BNO 1016 480 mg
(n = 294)
Placebo
(n = 295)
BNO 1016 480 mg
(n = 213)
Placebo
(n = 220)
Visit 2 (day 3) 57.8% 55.6% 60.6% 55.9%
p value*† = 0.5455 p value*† = 0.3243
Visit 3 (day 7) 86.1% 78.0% 89.7% 76.4
p value*† = 0.0076 p value*† = 0.0002
Visit 4 (day 10) 90.8% 80.7% 95.8% 80.5%
p value*† = 0.0002 p value*† < 0.0001
Visit 5 (day 14) 93.2% 85.1% 94.8% 83.6%
p value*† = 0.0016 p value*† = 0.0002
*Two-sided; alpha = 0.05.
†Cochran–Mantel–Haenszel test.
FAS, full analysis set; PP, per-protocol population.
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in the treatment of acute viral rhinosinusitis. This new
treatment concept – in what is usually a self-limiting
disease – gives faster recovery from symptoms, gives a
higher rate of complete recovery as compared with
placebo, and improves quality of life in patients.
Results for FAS were exceeded by the PP analysis
set throughout the study.
Until now there has been limited knowledge of the
beneﬁcial effects of herbal medicines in the treatment
of ARS. Pharmacodynamic studies on BNO 1011
57.8%
86.1%
90.8% 93.2%
55.6%
78.0% 80.7%
85.1%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Visit 2 (Day 3) Visit 3 (Day 7) Visit 4 (Day 10) Visit 5 (Day 14)
p = 0.2728 p = 0.0038 p = 0.0001 p = 0.0008
BNO 1016 480 mg (n = 294)
Placebo (n = 295)
Figure 3. ARhiSi combined analysis of ARhiSi-1 and ARhiSi-2: responder (healed or improved) to treatment from visit 2 (day 3) to visit 5 (day
14) (FAS, full analysis set; n = 589).
Table IV. SNOT-20: total score from visit 3 (day 7) to visit 5 (day 14) (FAS).
FAS, mean (SD) PP, mean (SD)
SNOT-20 total score
BNO 1016 480 mg
(n = 288)
Placebo
(n = 291)
BNO 1016 480 mg
(n = 213)
Placebo
(n = 218)
Visit 1 (day 0), baseline 41.24 (13.32) 41.24 (13.52) 40.87 (12.22) 40.06 (12.15)
Visit 3 (day 7) 24.55 (14.71) 27.00 (15.11)‡ 23.09 (13.66) 26.84 (14.67)
Visit 5 (day 14) 12.49 (13.78) 16.41(16.43) 10.47 (12.10) 16.11 (15.99)
p value*† p = 0.0015 p < 0.0001
*One-sided; alpha = 0.025.
†Repeated measures ANCOVA.
‡Two SNOT-20 calculations were not evaluable.
FAS, full analysis set; PP, per-protocol population; SD, standard deviation.
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have demonstrated both antiviral activity [13] and
stimulation of beat frequency in human respiratory
epithelia in vitro by activation of forskolin-stimulated
chloride secretion [14]. BNO 1011 is a dry extract
without excipients whereas for BNO 1016 excipients
are added for technical reasons, for example, to enable
the extract to be pressed into tablets.
The clinical evidence for BNO 101 (Sinupret) (with
the same constituents as BNO 1016 but in a lower
dose) in the treatment of sinusitis has recently
been reviewed, showing a favorable effect [15].
This herbal medicinal product exerts signiﬁcant
oral anti-inﬂammatory effects by a reduction of cyclo-
oxygenase (COX)-2 expression and prostaglandin
(PG)E(2) formation [16]. Thus, the mode of action
rationalizes its therapeutic use in the treatment of
sinusitis and other viral/microbial nasal infections
that are associated with inﬂammation. Experimental
studies on Sinupret show a reduction of bacterial
growth after only 4 days [6]. Other herbals – although
chemically less deﬁned than Sinupret – seem similarly
to have some anti-inﬂammatory effect, for example, in
chronic sinusitis [17].
Although intranasal corticosteroids (alone or in
combination with antibiotics) are generally recom-
mended for ARS there seems to be a need for further
documentation of their clinical use [18]. A recent
meta-analysis of the efﬁcacy of the intranasal cortico-
steroid mometasone for the treatment of ARS showed
a ?????? (number needed to treat) of 11 for improving
or resolving symptoms [19]. For BNO 1016 an num-
ber needed to treat of 10 was calculated for the pooled
data set. Thus, herbal drug BNO 1016 seems at least
equally beneﬁcial – or even more beneﬁcial – than
some locally applied corticosteroids in the treatment
of ARS.
The use of MSS in our analysis is in accordance
with the EPOS 2012 recommendations combining
the ﬁve most relevant symptoms of ARS and is often
used as a standard for primary efﬁcacy criteria in
clinical studies [1]. Furthermore, ultrasonography
conﬁrmed the treatment effect [8]. Our analysis
together with the ARhiSi-2 study on the clinical
efﬁcacy of BNO 1016 [8] are the ﬁrst well-controlled
investigations (to assess the effect of a ﬁxed dose
combination of herbs) fulﬁlling all the current quality
standards to be prospective, double blind, random-
ized, and placebo-controlled.
There is no gold standard treatment for ARS.
Antibiotics are not indicated in the treatment of
uncomplicated ARS. The great number of different
viruses causing ARS has made it difﬁcult to manu-
facture an effective vaccine. The socio-economic costs
of this disease are tremendously high, requiring
health-care resources, and lead to loss of productivity
[3]. On average, every adult becomes affected by
upper respiratory disease two to ﬁve times per year.
In this perspective every treatment modality shorten-
ing the length of the disease and improving the quality
of life of individual patients is beneﬁcial both for
society and for the individual.
As no SAEs occurred with BNO 1016 and as the
frequency and intensity of AEs are similar for BNO
1016 and placebo, it can be concluded that BNO
1016 has a similar safety proﬁle to placebo. Accord-
ingly, BNO 1016 has a favorable beneﬁt/risk ratio.
In conclusion, this analysis conﬁrms the results of
the conﬁrmatory phase 3 trial with BNO 1016. The
analysis has demonstrated that daily intake of 480 mg
BNO 1016 for 2 weeks is a safe and effective treatment
option in uncomplicated ARS. The drug provides a
faster and clinically relevant remission of symptoms
and improves quality of life as compared with placebo.
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